Skip to main content
Fig. 3 | Insights into Imaging

Fig. 3

From: Do we still need breast cancer screening in the era of targeted therapies and precision medicine?

Fig. 3

Effect of screening and novel systemic treatments on breast cancer recurrences among women aged 60 to 74 years, diagnosed with breast cancer between 2000 and 2013. Stage distribution was derived from Puliti et al. [21] considering attenders and non-attenders to screening mammography; a 5% overdiagnosis attributed to screening mammography was taken into account. HR+ and HR− recurrences are back-calculated from Mariotto et al. [24]. The most favourable scenario arises from the use of mammography screening associated with novel systemic treatments. BCs, breast cancers; HR+, hormone receptor-positive breast cancers; HR−, hormone receptor-negative breast cancers

Back to article page